Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...
Eliem Therapeutics Inc (NASDAQ:ELYM), a company focused on developing therapies for pain, epilepsy, and depression, reported a significant insider transaction. Valerie Morisset, the Executive Vice President, Research & Development and Chief Scientific Officer, sold 41,783 shares of the company on July 18, 2024. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 160,523 shares of Eliem Therapeutics Inc.
Over the past year, the insider has sold a total of 352,433 shares and has not purchased any shares. This latest transaction continues a trend of insider sales at the company, with 7 insider sells recorded over the past year compared to only 1 insider buy.
Shares of Eliem Therapeutics Inc were priced at $6.93 on the day of the transaction, placing the company's market cap at approximately $467.833 million. The company's valuation metrics, including GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow are key indicators for potential investors.
The insider transaction trends at Eliem Therapeutics Inc can be visualized in the following chart:
This insider sale may be of interest to current and potential investors, providing insights into insider confidence and company performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.